These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 2160321)

  • 1. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.
    Conlon KC; Ochoa AC; Kopp WC; Ortaldo JR; Urba WJ; Longo DL; Young HA
    J Immunol; 1992 Nov; 149(10):3278-89. PubMed ID: 1358968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
    Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro.
    Dett CA; Gatanaga M; Ininns EK; Cappuccini F; Yamamoto RS; Granger GA; Gatanaga T
    J Immunol; 1991 Mar; 146(5):1522-6. PubMed ID: 1847164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.
    Crump WL; Owen-Schaub LB; Grimm EA
    Cancer Res; 1989 Jan; 49(1):149-53. PubMed ID: 2783241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation.
    Damle NK; Doyle LV
    Lymphokine Res; 1989; 8(2):85-97. PubMed ID: 2525210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study.
    Naume B; Espevik T
    J Immunol; 1991 Oct; 147(7):2208-14. PubMed ID: 1717551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
    Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
    Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 induces tumor necrosis factor-alpha production by activated human T cells via a cyclosporin-sensitive pathway.
    Lorré K; Fransen L; Ceuppens JL
    Eur Cytokine Netw; 1992; 3(3):321-30. PubMed ID: 1353987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 activates human gamma delta T cells: synergistic effect of tumor necrosis factor-alpha.
    Ueta C; Kawasumi H; Fujiwara H; Miyagawa T; Kida H; Ohmoto Y; Kishimoto S; Tsuyuguchi I
    Eur J Immunol; 1996 Dec; 26(12):3066-73. PubMed ID: 8977306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.